Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled time : 12:15 save search
IN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme
Published: 2021-10-27 (Crawled : 12:15) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 0.37%
H: 3.05%
C: -7.81%
results preclinical t-cell pre-clinical glioblastoma
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
Published: 2021-09-07 (Crawled : 12:15) - biospace.com/
RDY | $70.91 -0.56% 0.0% 97K
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: -0.48%
CTXR | $0.8 -1.99% -2.02% 6.3M
|
Health Technology
|
| O: 3.37%
H: 5.93%
C: -1.4%
treatment immunotherapy therapy cancer license phase 3 t-cell e7777
JinkoSolar Receives Favorable Summary Affirmance of Non-Infringement from the U.S. Court of Appeals for the Federal Circuit in U.S. ITC Patent Investigation Brought by Hanwha Q CELLS
Published: 2021-07-27 (Crawled : 12:15) - prnewswire.com
JKS | News | $21.66 -0.14% -1.15% 970K
|
Producer Manufacturing
|
| O: -6.47%
H: 2.58%
C: -7.89%
solar patent t-cell
Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma
Published: 2021-07-16 (Crawled : 12:15) - globenewswire.com
FATE | $5.04 -4.36% -4.56% 2.3M
|
Health Technology
|
| O: 1.94%
H: 2.05%
C: 0.45%
phase 1 t-cell
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum
Published: 2021-07-12 (Crawled : 12:15) - globenewswire.com
KYMR | $35.16 4.15% 3.98% 620K
|
Health Technology
|
| O: 5.13%
H: 0.0%
C: -5.58%
t-cell preclinical pre-clinical
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-06-25 (Crawled : 12:15) - biospace.com/
XNCR | $18.98 -0.47% -0.47% 470K
|
Health Technology
|
| O: 0.06%
H: 2.35%
C: 0.75%
MOR | $18.02 -0.11% -0.11% 590K
|
Health Technology
|
| O: 2.89%
H: 0.23%
C: -0.55%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.71%
H: 1.74%
C: 1.53%
treatment positive chmp t-cell
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
Published: 2021-04-28 (Crawled : 12:15) - globenewswire.com
NKTX | $7.78 -1.02% -1.03% 680K
|
Health Technology
|
| O: 0.27%
H: 1.03%
C: -0.85%
food treatment drug clearance t-cell
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.